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Tamara Tanos,1 George Sflomos,1 Pablo C. Echeverria,2 Ayyakkannu Ayyanan,1
Maria Gutierrez,1 Jean-Francois Delaloye,3 Wassim Raffoul,3 Maryse Fiche,3 William Dougall,4
Pascal Schneider,5 Ozden Yalcin-Ozuysal,6 Cathrin Brisken1*Estrogens and progesterones are major drivers of breast development but also promote carcinogenesis in this organ.
Yet, their respective roles and the mechanisms underlying their action in the human breast are unclear. Receptor
activator of nuclear factor kB ligand (RANKL) has been identified as a pivotal paracrine mediator of progesterone
function in mouse mammary gland development and mammary carcinogenesis. Whether the factor has the same
role in humans is of clinical interest because an inhibitor for RANKL, denosumab, is already used for the treatment of
bone disease and might benefit breast cancer patients. We show that progesterone receptor (PR) signaling failed to
induce RANKL in PR+ breast cancer cell lines and in dissociated, cultured breast epithelial cells. In clinical specimens
from healthy donors and intact breast tissue microstructures, hormone response was maintained and RANKL expres-
sion was under progesterone control, which increased RNA stability. RANKL was sufficient to trigger cell proliferation
and was required for progesterone-induced proliferation. The findings were validated in vivo where RANKL protein
expression in the breast epithelium correlated with serum progesterone levels and the protein was expressed in a
subset of luminal cells that express PR. Thus, important hormonal control mechanisms are conserved across species,
making RANKL a potential target in breast cancer treatment and prevention.INTRODUCTION
Breast cancer is a leading cause of cancer-associated death worldwide.
The ovarian hormones estrogens and progesterone control breast de-
velopment and promote carcinogenesis in this organ (1). Their respec-
tive roles are debated, and the mechanisms underlying their action
in vivo are poorly understood.
Mouse genetics combined with tissue recombination approaches
have revealed that estrogens and progesterone act through their cog-
nate receptors expressed in a subset of mammary epithelial cells to
elicit cell proliferation largely by paracrine mechanisms (2). Estrogens
drive pubertal development relying on amphiregulin as a paracrine
mediator of their proliferative effects (3, 4), whereas progesterone is
the major proliferative stimulus in the adult mammary gland and acts
through both cell-intrinsic and paracrine mechanisms (5).
The tumor necrosis factor (TNF) family member RANKL (receptor
activator of nuclear factor kB ligand), originally identified as a dendritic
cell factor and well characterized for its function in osteoclast differen-
tiation (6), is also required for mammary gland development (7). Ge-
netic evidence was provided that RANKL is important as a paracrine
mediator of progesterone-induced proliferation in the adult mouse
mammary gland (8, 9). Systemic inhibition of RANKL signaling by
intravenous injection of recombinant osteoprotegerin (rOPG), its de-
coy receptor, blocked progesterone-induced proliferation in the mam-
mary epithelium (8), suggesting that RANKL may be used as a drug
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www.Scieto be involved in expansion of mammary stem cells that have been
characterized by high cell surface expression of integrins a6 (CD49f)
and b1 (CD29) by fluorescence-activated cell sorting (FACS) (10, 11).
The cell populations expressing high levels of CD49f or CD29 are
enriched for cells with the ability to reconstitute mammary fat pads
divested of the endogenous epithelium in low numbers (12, 13). How-
ever, the physiologic relevance of multipotent stem cells identified by
this experimental approach was questioned by recent publications,
suggesting that lineage-restricted stem cells drive normal development
(14, 15). Beyond these physiological roles, RANK signaling was shown
to be important to mammary tumorigenesis; both genetic and phar-
macological inhibition interfered with tumor progression in different
mammary tumor models (16, 17) and metastasis, the latter by a T
cell–dependent mechanism (18). A RANKL-inhibiting antibody,
denosumab (Amgen), has been U.S. Food and Drug Administration
(FDA)–approved for treatment of postmenopausal women at high
risk for fracture and for prevention of skeletal-related events in pa-
tients with bone metastases. Hence, whether the findings in the mouse
model apply to humans and whether denosumab may have a place in
breast cancer prevention and/or treatment is an urgent question.
The hormone receptor–positive breast cancer cell lines MCF-7 or
T47D are widely used models to study hormone action and have
yielded detailed knowledge on molecular mechanisms underlying es-
trogen receptor (ER) and progesterone receptor (PR) signaling, respec-
tively (19). However, genes modulated by hormone signaling in these
cell lines differ from target genes identified in mice in vivo (20). Pri-
mary human breast epithelial cells (HBECs) grown in vitro lose steroid
hormone receptor expression, and therefore, they cannot be used to
study estrogen and progesterone action. The importance of extra-
cellular matrix, three-dimensional (3D) structure, and matrix stiffness
for mammary epithelial cell biology has been well documented (21, 22),
and the effects of these factors on cell signaling have been extensively
characterized. However, even in a sophisticated 3D culture approach innceTranslationalMedicine.org 24 April 2013 Vol 5 Issue 182 182ra55 1
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stream targets identified in the mouse mammary gland, Wnt-4 and
RANKL, are not induced by progesterone (23).
This leads to the question of whether different in vitro systems do
not adequately reflect the in vivo complexities or whether the discrep-
ancies are due to differences in regulatory networks between humans
and mice. Indeed, differences in tissue composition, the physiology of
human menstrual and murine estrous cycle, as well as hormone levels
may limit the relevance of findings in mice to humans.
Here, we argue that steroid hormone signaling, which relies on
paracrine factors, can only be studied adequately in the context of tis-
sue samples with intact architecture. By extension, previous models in
which cells are dissociated before being embedded into matrixes failed
to preserve this signaling context. On the basis of our hypothesis, we
developed an ex vivo model using breast tissue microstructures
isolated from fresh clinical specimens that preserve extensive inter-
cellular contacts and contain multiple cell types. We show that these
structures remain hormone-responsive; more specifically, progester-
one induces cell proliferation with RANKL, whose mRNA stability
is increased, as an essential mediator. Our findings suggest that impor-
tant growth control pathways in the breast are conserved between
mouse and human and that PR/RANKL signaling may be targeted
in breast cancer prevention and treatment.RESULTS
Development of an ex vivo model to study hormone action
in the human breast
To study the role of estrogens and progesterone in the human breast,
we collected fresh human breast tissue specimens from 151 patients
undergoing reduction mammoplasties after obtaining their informed
consent. We obtained their medical and reproductive history and a
blood sample to determine serum progesterone levels at the time of
surgery (table S1). A biobank was built with tissue stored in paraffin,
flash-frozen, and processed for storage in freezing medium. The frozen
samples were used to establish the ex vivo approach described here-
after. All experiments shown below were performed with freshly iso-
lated tissue to avoid possible artifacts due to freezing.
We reasoned that it is important to preserve intercellular interac-
tions to study hormone action in the breast epithelium because steroid
hormone action relies largely on paracrine signaling (24). Tissue from
fresh reduction mammoplasties was mechanically and enzymatically
dissociated (Fig. 1A). The resulting tissue fragments of up to 2 mm
in size have ducts and lobules that reflect their anatomic site of origin
(Fig. 1B). Hence, we refer to them as “tissue microstructures” in con-
trast to the term “organoids” that designates tissue fragments isolated
from the mouse mammary gland previously used to study progester-
one response (25), which are round and amorphous (Fig. 1C). The
tissue microstructures were suspended in minimal medium; cell via-
bility remained more than 90% until after 6 days of culture as assessed
by trypan blue staining (Fig. 1D). The breast tissue microstructures
derived from seven different patients contained between 1 and 24%
of proliferating cells after 24 and 48 hours, as assessed by immuno-
staining for the S/M phase–specific marker phospho–histone H3 (Fig.
1E). To exclude the formal possibility that cells were stalled in S/M
phase in the ex vivo condition, we exposed freshly isolated tissue mi-
crostructures to two different nucleotide analogs; during the firstwww.Scie24 hours of culture, they were exposed to 5-bromo-2′-deoxyuridine
(BrdU) and, after washing, to 5-ethynyl-2′-deoxyuridine (EdU) for
the subsequent 24 hours. Double immunofluorescence revealed that
both analogs were incorporated into distinct cells (Fig. 1F), indicating
that cells were synthesizing DNA, hence actively progressing through
the cell cycle in the ex vivo model. Thus, in the context of these tissue
microstructures, cell proliferation occurred even in the absence of ex-
ogenous growth factors. This contrasts with HBECs plated on plastic,
which, like cultured cell lines, do not proliferate when kept in growth
factor– and serum-free medium (26).
To further characterize the microstructures, we performed immu-
nostaining for the intermediate filaments CK18, specific for luminal
cells, and CK14, expressed in basal cells of ducts and both luminal
and basal cells in the lobules, as well as the basal/myoepithelial marker
p63. The stainings revealed that the major cell types and the bilayered
structure of the human breast epithelium are maintained in the ex vivo
model (Fig. 1G). Next, we assessed the expression of hormone recep-
tors, which is lost upon in vitro culture of primary HBECs. In the
tissue microstructures, about 30% of the epithelial cells expressed
ERa and PR on day 4 (Fig. 1J), similar to what is observed in the nor-
mal human breast (27). To address whether the continued expression
of hormone receptors related to the preserved intercellular contacts in
the tissue microstructures or to the suspension culture, we dissociated
tissue microstructures to single cells and plated them in suspension on
low attachment plates. Quantification of PR expression in such sam-
ples from three different patients revealed that initially 3.3% of the
cells expressed PR, consistent with a large number of stromal cells
in the tissue microstructures. This percentage decreased to 0.4% on
day 4 (Fig. 1, H and I). Thus, suspension culture per se did not prevent
loss of hormone receptor expression, but preserving tissue structure is
likely important to maintain hormone receptor expression.
To test whether hormone receptor signaling is intact in the ex vivo
system, we exposed tissue microstructures for 24 hours to either vehi-
cle or E2 and determined protein levels of the ERa target gene PR. In
three patient samples, PR protein levels were increased by the E2 treat-
ment (Fig. 1K). In an additional sample, the response to E2 was tested
on three subsequent days, and PR protein expression was consistently
induced (Fig. 1L). Thus, ERa signaling remains functional for at least
3 days in the ex vivo model.
Cell proliferation in response to activation of
ERa and PR signaling
Next, we examined the effects of ERa and PR signaling activation on
cell proliferation. To activate the two pathways, we used E2 (20 nM)
and the stable PR agonist R5020 (20 nM), respectively. Tissue micro-
structures from 29 different patients were processed and stained for
phospho–histone H3 after 24 hours of stimulation. Stimulation with
E2 did not elicit statistically significant changes in the proliferative
index, but tissue microstructures stimulated with R5020 had an aver-
age increase of twofold (P = 0.01) (Fig. 2A). Surprisingly, combined E2
and R5020 treatment did not induce significant increase in cell prolif-
eration (P = 0.16).
Human breast tissue samples are very heterogeneous. Within a given
breast, cellularity and cell type composition can vary between different
sectors. Moreover, histological features differ largely among different
patients (fig. S1). Patients were of different ages (17 to 78 years) (table
S1) and had distinct reproductive histories and different endocrine
milieus at the time of surgery. Moreover, several patients used oralnceTranslationalMedicine.org 24 April 2013 Vol 5 Issue 182 182ra55 2
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nous hormones and their analogs.
We asked whether discrete response patterns might underlie the
large variation. Using Cytoscape software (28, 29), we organized the
samples in a correlation network according to their proliferative re-
sponses to E2 and R5020, alone or in combination, compared to vehicle,
as well as the comparison of the response to R5020 to either E2 alone or
the combination of the two. Five different groups were distinguished
(Fig. 2B); the largest number of samples was characterized by a clearwww.Scieproliferative response to progesterone and an inhibitory effect on cell
proliferation by E2 (group 1) (Fig. 2B). Groups 2 and 3 showed in-
creased cell proliferation in response to progesterone but also to E2 to
different extent. Group 4 comprised nonresponders, and group 5 was
characterized by a proliferative response specifically to E2; two of three
samples in group 5 were from patients under 20 years of age. No
statistically significant correlation between contraceptive pill intake,
menstrual cycle status, and parity and the proliferative response to E2
and R5020 was found in the present small patient cohort (n = 29).Fig. 1. Ex vivo system for hormone action in the human breast. (A)
Scheme of the experimental setup. (B) Human tissue microstructures fresh-
incorporated either nucleotide. (G) Histological sections of tissue micro-
structures paraffin-embedded after 48 hours in culture immunostainedly isolated from reduction mammoplasty specimen. Scale bar, 100 mm. (C)
Mouse organoids freshly isolated from mammary glands. Scale bar, 100 mm.
(D) Ex vivo tissue microstructures in suspension at different days, stained
with trypan blue to reveal dead cells. Until day 6, more than 90% of the
cells are viable. Scale bar, 1 mm. (E) Bar plot showing cell proliferation
index ± SD in tissue microstructures cultured without growth factors as
determined by phospho–histone H3 immunostaining 24 and 48 hours af-
ter isolation (n = 7 for either time point). (F) Anti-BrdU (green) and anti-EdU
staining (red) of tissue microstructures that were exposed to BrdU during
the first 24 hours in culture and to EdU during the ensuing 24 hours, coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI). Several cells havewith anti–cytokeratin 18 (CK18), anti-CK14, and anti-p63 antibodies. Note
that the bilayered structure of the human breast epithelium is maintained.
Scale bars, 100 mm. (H) Immunofluorescence for PR (red) counterstained
with DAPI (blue) after cytospin of dissociated organoids that were grown
in suspension for 24, 48, 72, and 96 hours. Scale bar, 100 mm. (I) Bar plot
showing quantification of PR+ cells (mean percentage ± SD) (n = 3). (J)
Immunostaining of tissue microstructures on day 4 of culture for ERa
and PR. (K) Immunoblots stained with PR and tubulin antibodies on lysates
from tissuemicrostructures from three different patients exposed for 24 hours
to either vehicle or 17b-estradiol (E2). (L) A fourth patient’s sample was ex-
posed to either vehicle or E2 on day 1, 2, or 3 of culture.nceTranslationalMedicine.org 24 April 2013 Vol 5 Issue 182 182ra55 3
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in samples from 35- to 45-year-old patients.
Effects of PR signaling on RANKL expression
The data indicate that progesterone acts as a proliferative stimulus in
the adult human breast. In the mouse mammary gland, progesterone
elicits cell proliferation largely by a paracrine mechanism that requires
expression of the PR target gene RANKL (8). Treatment of PR+ breast
cancer cell lines, T47D and MCF-7, as well as primary HBECs withwww.ScieR5020 did not induce RANKL protein expression (Fig. 3A). Similarly,
RANKL mRNA induction had not been detected in primary HBECs
grown in Matrigel (23). When R5020 was added to freshly prepared
tissue microstructures, RANKL mRNA levels increased 230% within
4 hours (n = 11, P = 0.003) (Fig. 3B). Similarly, RANKL protein levels
in tissue microstructures were consistently increased upon 24 hours of
R5020 treatment (Fig. 3C). Some induction by E2 was observed in two
of three patients tested.
Progesterone and RANKL have been implicated in the control of
pluripotent mouse mammary stem cells via RANK, the cognate recep-
tor of RANKL, and RANK mRNA expression was shown to be en-
riched in the basal cell population of the mouse mammary gland that
comprises the stem cells (10, 11). In the human breast, stem cells have
similarly been shown to reside in the basal compartment, which is
characterized by cell surface expression of CD10 (30). To test whether
progesterone stimulation results in expansion of the CD10+ cell pop-
ulation, we purified different cell types from tissue microstructures
that had been exposed to R5020 or vehicle for 24 hours. The micro-
structures were dissociated and depleted from immune cells, fibro-
blasts, and endothelial cells with a cocktail of anti-CD45, anti-Fap,
and anti-CD31 antibodies. Subsequently, cells were FACS-sorted on
the basis of expression of the pan-epithelial marker EpCAM and CD10.
This approach distinguishes three cell populations: EpCAMhigh/CD10−
enriched for luminal cells, EpCAMlow/CD10+ containing basal cells,
and an EpCAM−/CD10− double-negative population (Fig. 3D) (30).
By this approach, we did not detect significant changes in the ratio
of different cell populations upon R5020 stimulation in nine patient
samples (Fig. 3E). Quantitative reverse transcription polymerase chain
reactions (qRT-PCRs) for myoepithelial-specific p63 and the luminal
CK18 mRNA showed expected enrichment in the separated popula-
tions, and there were no significant changes in the expression levels of
the basal markers CD10 and p63 within the sorted cell populations
(Fig. 3F). The mRNA for the cognate RANKL receptor RANK was
enriched in the EpCAMhigh luminal cell population characterized by
CK18 expression (Fig. 3F).
Consistent with RANKL being expressed in PR+ luminal cells, its
mRNA was enriched in EpCAMhigh cells (fig. S2). R5020 stimulation
of tissue microstructures increased RANKL mRNA levels up to 40-fold
in the EpCAMhigh populations of the three patient samples analyzed
(Fig. 3G). Similarly, another progesterone target gene well established
in the mouse mammary gland, Wnt-4 (31), which, like RANKL, was
not induced in the in vitro Matrigel system (23), was induced up to
sevenfold in the EpCAMhigh population after 24 hours of progesterone
stimulation (Fig. 3G). Thus, two essential in vivo PR targets, RANKL
and Wnt-4, are induced in the tissue microstructures by activation of
PR signaling in human luminal breast epithelial cells.
Role of RANKL in progesterone-induced cell proliferation
To test whether RANKL stimulation is sufficient to induce cell prolif-
eration, we added recombinant RANKL (rRANKL) protein (1 mg/ml)
to tissue microstructures from 16 different patients for 24 hours. Im-
munostaining for RANKL on fixed tissue microstructures detected
RANKL protein without tyramide signal amplification (TSA) required
to detect endogenous RANKL expression (Fig. 4, A and B), indicating
that the rRANKL reaches cells inside the tissue microstructures. RANKL
stimulation induced a 2.5-fold increase in the proliferative index as
assessed by phospho–histone H3 staining (n = 16, P < 0.02) (Fig. 4C),
and this occurred in a dose-responsive manner (Fig. 4D).EtOH E2 R5020 E2 & R5020
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Fig. 2. Hormone-induced cell proliferation in breast tissue microstruc-
tures. (A) Box plot showing cell proliferation index as determined by im-
munofluorescence for phospho–histone H3 of DAPI-counterstained nuclei
in tissue microstructures exposed for 24 hours to vehicle [ethanol (EtOH)],
E2, R5020, or E2 and R5020. Only R5020 induced statistically significant cell
proliferation (P = 0.01, two-tailed Student’s t test; n = 29). (B) Network cor-
relation organization and analysis of cell proliferation in response to hor-
mone stimulation in 29 patient samples reveals five distinct response
patterns (groups 1 to 5) described in the main text. Nodes (samples) were
colored with a red-to-blue gradient according to fold change in cell prolif-
eration of pairwise comparisons (see inset for color gradient).nceTranslationalMedicine.org 24 April 2013 Vol 5 Issue 182 182ra55 4
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RANKL signaling,wemadeuse of the decoyRANKL receptorOPG.Tissue
microstructures were stimulatedwithR5020 for 24 hours in the presence orwww.ScienceTranslationalMedicine.orgabsence of rOPG. Analysis of three different
patients showed that addition of rOPG
(10 mg/ml) abrogated, on average, 80% of
the R5020-induced cell proliferation (P =
0.01) (Fig. 4E). The basal proliferative in-
dices differ substantially between patients
(Fig. 4E). In three additional patient sam-
ples, a higher dose of rOPG (20 mg/ml)
was included, which showed a stronger in-
hibition (Fig. 4F). Similar results were ob-
tained at 48 hours (n = 3) (Fig. 4G). Thus,
RANKL is sufficient to induce proliferation
of HBECs and is required for PR signaling–
induced cell proliferation.
RANKL expression in vivo
To assess whether the observations in the
ex vivo model are relevant to the human
breast in vivo, we used the biobank of re-
duction mammoplasty specimens (n =
151) (table S1). More specifically, we iden-
tified 16 patients who had high serum
progesterone levels when their breast tis-
sue was surgically removed. We were able
to age-match 10 of these patients with pa-
tients who had low progesterone levels
and did not take exogenous hormonal prep-
arations. In the paraffin-embedded breast
tissue samples from these 10 control sam-
ples, that is, women with low serum pro-
gesterone levels (<4 nM), we failed to
detect RANKL protein by immunohisto-
chemistry. The protein was readily de-
tected in all 10 samples derived from
women with high serum progesterone
levels (15 to 62 nM) (Fig. 5, A and B). Fur-
thermore, during pregnancy, when proges-
terone levels increase further (>300 nM),
RANKL expression was particularly high,
with more widespread expression and a
stronger fluorescence signal (Fig. 5, A
and B). Thus, RANKL protein expres-
sion correlates with serum progesterone
levels in the human breast in vivo.
Double immunofluorescence for
RANKL and PR revealed that between
51 and 78% of the PR+ cells showed de-
tectable RANKL expression (Fig. 5, C and
D). Conversely, on average, 97% of RANKL+
cells show detectable PR expression (Fig.
5, C and D). Together, our data strongly
support the hypothesis that RANKL ex-
pression is controlled by progesterone in
the human breast epithelium in vivo.Control of RANKL mRNA expression by progesterone
Having ascertained that control of RANKL expression by progester-
one in the breast epithelium is conserved between mice and humans,Fig. 3. Control of RANKL expression by PR signaling. (A) Immunoblot of MCF-7, T47D, and primary HBECs
cultured on plastic dishes untreated or exposed to either vehicle (EtOH) or R5020 for 24 hours. RANKL pro-
tein levels are not affected by R5020. (B) Relative RANKL mRNA levels normalized to hypoxanthine-guanine
phosphoribosyltransferase (HPRT) mRNA were assessed by RT-PCR in tissue microstructures from 10 dif-
ferent patients that were treated with vehicle or R5020 for 4 hours. Large black dots represent means ± SD.
(C) Immunoblot of protein lysates from tissue microstructures exposed for 24 hours to either vehicle (EtOH),
E2, R5020 (R), or E2 and R5020 (E2 & R), representative of three independent experiments. (D) FACS scatter-
grams showing different epithelial cell populations isolated from tissue microstructures after 24 hours of in-
cubation with vehicle or R5020. Stromal cells were first depleted with anti-CD31, anti-CD45, and anti-Fap
antibodies (cocktail), and remaining cells were stained with anti-CD10 and anti-EpCAM antibodies. (E) The
ratio between the different cell populations ± SD in tissue microstructures is not significantly affected by
the R5020 treatment [n = 9; EpCAM+, P = 0.77; CD10+, P = 0.81; double-negative (DN), P = 0.81]. (F) Marker
gene expression in FACS-sorted cell populations from dissociated breast tissue microstructures exposed for
24 hours to either vehicle (closed bars) or R5020 (open bars). Relative mRNA expression levels of CK18, RANK,
p63, and CD10 were normalized to HPRT. Graphs represent means ± SD of independent experiments per-
formed on tissue from four different patients. Note that RANK mRNA expression is enriched in the EpCAM+
luminal cell compartment. (G) Bar plots showing relative mRNA expression levels of RANKL (left) and Wnt-4
(right) normalized to HPRT in FACS-sorted EpCAM+ cells from tissue microstructures exposed for 24 hours to
either vehicle (EtOH) or R5020. Experiment is representative of three independent experiments.24 April 2013 Vol 5 Issue 182 182ra55 5
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nisms by which progesterone signaling affects RANKL expression.
Treatment of freshly isolated mammary organoids with R5020 led
to an average 400% increase in RANKL mRNA levels within 30 min
(Fig. 6A). RANKL may be a direct transcriptional target of PR sig-
naling; however, there are no well-defined PR binding sites in the
RANKL promoter. To address whether R5020 affects the half-life (T1/2)
of RANKL mRNA, we treated primary mouse mammary epithelial
cells with the transcription inhibitor actinomycin in the presence or
absence of R5020. In the absence of R5020, the T1/2 of RANKL mRNA
was 1 hour, whereas in the presence of R5020, the levels of RANKL
mRNA were more than 90% of the pretreatment levels after 2 hours
(Fig. 6B), indicating a T1/2 of more than 6 hours. Control mRNAs
such as CK14, CK18, and 36B4 had half-lives greater than 6 hourswww.ScienceTranslationalMedicine.orgindependent of R5020 (Fig. 6C). Next, we
quantified the levels of the primary tran-
script by real-time RT-PCR with primers
spanning the first exon-intron junction and
the mature transcript, using primers with-
in different exons (Fig. 6E, P0 and M0).
Organoids that had been stimulated with
R5020 for 4 hours showed, on average, a
37-fold increase in the levels of the ma-
ture message, whereas the levels of the pri-
mary transcript increased only twofold in
three independent experiments (Fig. 6D).
We designed more primer sets in which
an exon-specific primer is shared and the
second primer is either intron-specific (pri-
mary transcript) or exon-specific (mature
transcript) and chose three primer sets
that amplified the two transcripts with equal
efficiency (Fig. 6E). Again, the primary
transcript was, on average, induced 2.2-
fold, whereas the mature transcript was in-
duced 9.1-fold. Thus, in mouse mammary
organoids, PR signaling controls RANKL
mRNA levels predominantly at the mRNA
maturation/stability rather than at the tran-
scriptional level.
To assess whether the same applies to
human breast epithelium, we used FACS
sorting and enriched with EpCAM for
PR/RANKL-expressing cells. We selected
three distinct primer pairs for primary and
mature transcript of equal amplification
efficiency and made use of microfluidics
(Fluidigm) to analyze the expression in
the EpCAMhigh cells from stimulated tis-
sue microstructures from three different
patients. Expression of the primary tran-
script was induced, on average, 1.7-fold,
whereas the mature transcript was induced
7.5-fold (Fig. 6E), suggesting that also in
the human breast, RANKL mRNA ex-
pression is controlled, at least partially, by
posttranscriptional mechanisms.DISCUSSION
The goal of this study was to address the long-standing need for a
model system to study hormone action in the human breast and to
determine what controls cell proliferation in the human breast epithe-
lium. We developed an ex vivo model based on tissue microstructures
isolated from fresh breast specimens that maintains the cellular orga-
nization of breast epithelium, expression of ERa and PR, and respon-
siveness to hormones. Using this model, we demonstrate that PR
signaling induces cell proliferation. This is consistent with the clinical
observation that cell proliferation occurs during the luteal phase when
serum progesterone levels are elevated (32). In this system, two important
mediators of progesterone action identified in the mouse, RANKL and
Wnt-4 (8, 31, 33), are induced by PR signaling. RANKL is required andFig. 4. RANKL and PR signaling and cell proliferation. (A and B) Anti-RANKL immunostaining of hu-
man tissue microstructures exposed to vehicle (A) or rRANKL (1 mg/ml) (B) without TSA amplification, rep-
resentative of three independent samples. Scale bars, 100 mm (inset, 20 mm). (C) Bar graph showing
relative phospho–histone H3 (pHH3) index ± SD in tissue microstructures from 16 different patients treated
with vehicle (CTRL) or rRANKL (1 mg/ml). (D) Bar graph showing relative phospho–histone H3 index after
24 hours of stimulation with different doses of rRANKL, representative of three independent experiments.
(E) Bar plots showing phospho–histone H3 index in tissue microstructures isolated from three different
patients after 24 hours of treatment with vehicle (EtOH), R5020 (R), or R5020 and rOPG (10 mg/ml) (R + O).
(F) Bar plots showing relative phospho–histone H3 index in tissue microstructures isolated from three
different patients after 24 hours of treatment with vehicle, R5020, or R5020 and rOPG (10 mg/ml) (O10)
or rOPG (20 mg/ml) (O20). SD reflects counts taken on different sections of the same sample. (G) Bar plots
showing relative phospho–histone H3 index ± SD in tissue microstructures isolated from three different
patients after 48 hours of treatment with vehicle (EtOH), R5020, or R5020 and rOPG (10 mg/ml).24 April 2013 Vol 5 Issue 182 182ra55 6
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control pathway is conserved between mouse and human, and sug-
gests that at least some of the discrepancies reported between rodent
and human models relate to differences between in vivo and in vitro
approaches used for mouse and human, respectively. These findings
have important clinical implications. Selective PR modulators are
available, and a RANKL inhibitor, denosumab, has already been
FDA-approved for treatment of postmenopausal women at high
risk for fracture and for prevention of skeletal-related events in pa-
tients with bone metastases. The drugs may benefit breast cancer
patients as preventive and therapeutic agents.
With the advent of powerful chromatin immunoprecipitation
sequencing technology and the ENCODE project, most work on
steroid hormone action has focused on mapping steroid receptor
binding sites and transcriptional control mechanisms at the ge-
nome level (34). Our finding that a central physiological control
pathway works, to substantial extent, by controlling mRNA stabil-
ity suggests that posttranscriptional control mechanisms require
more attention.
In examining potential clinical applications, it will be important to
determine whether a wide spectrum of breast cancer patients may
benefit from denosumab, or whether its use will be limited to any
particular subtype of breast cancer (35). Considering the importance
of repeated progesterone stimulation as it occurs with menstrual cycles
as risk factor for breast cancer, the drug could, in particular, benefit
premenopausal patients with high risk of getting breast cancer because
it could abrogate the proliferative response elicited by the hor-
mone. Especially young breast cancer patients, such as those less than
40 years old, who are at a 5% risk of developing contralateral breastwww.Sciecancer within 10 years (36), could benefit from blocking RANKL
action during luteal phase and thus represent an excellent target group
for a first clinical study.
The observation that E2 inhibits cell proliferation in the largest
subgroup (group 1) is intriguing in light of recent studies that suggest
a protective effect of estrogens against breast cancer risk (37). Yet, cau-
tion is required in interpreting the different responses to E2 and pro-
gesterone. Much larger cohorts will be required to discern how oral
contraception, previous pregnancies, menopause, and other factors
may impinge on the response.
Surprisingly, E2, which induced PR expression, did not synergize
with progesterone with regard to cell proliferation and RANKL induc-
tion. However, there is PR expression in the absence of exogenous E2,
and this may be sufficient for a maximal response to progesterone.
Also, our expectations were based on experiments performed in ovari-
ectomized rodents where the two hormones act synergistically to in-
duce cell proliferation (38). Hormonally ablated mice and rats differ
from endocrine-intact animals, which might more closely reflect the
patients analyzed in the present study. Hormone signaling is extreme-
ly context-dependent, and there is increasing evidence for interactions
between ER and PR at the molecular level that may account for this
phenomenon (39).
The model reflects the context dependence that affects hormone
signaling. Minimal treatment of the clinical specimens, simple cul-
ture conditions with use of basal medium, and no serum ensure
that this assay is widely usable and reproducible. As such, the present
model opens new avenues for unraveling mechanisms underlying
the action of hormones and of hormonally active substances in the
breast.Fig. 5. In vivo RANKL expression and serum progesterone levels. (A)
Human breast tissue sections stained with anti-RANKL antibody. Repre-
protein over total number of samples analyzed in each group. (C) Coimmu-
nofluorescence for PR (red) and RANKL (green) in samples from three pa-sentative images of breast tissue sections from patients with low or high
serum progesterone levels (P) as well as from a pregnant patient. RANKL
(green) and DAPI counterstain (blue). Scale bars, 100 mm. (B) Table showing
number of human breast samples expressing detectable levels of RANKLtients with high serum progesterone levels. Scale bar, 50 mm. (D) Table
showing the age of six different patients with high progesterone serum
levels and the percentages of PR and RANKL coexpressing cells in their
tissue samples.nceTranslationalMedicine.org 24 April 2013 Vol 5 Issue 182 182ra55 7
R E S EARCH ART I C L EMATERIALS AND METHODS
Patients, tissue samples, and processing
The institutional ethics committee approved the study (45-05). To avoid
bias, we obtained breast tissue fromallwomenundergoing reductionmam-
moplasties from2005 to2012withnoprevioushistoryof breast cancer,who
gave informed consent. All experiments were performed on fresh tissue.
Replicates are on subsequent, hence random, mammoplasty specimens.www.ScieSamples were collected in the operating theater and confirmed by
the pathologists to be free of malignancy. Tissue was minced manually
to pieces of about 5-mm diameter and digested overnight at 37°C with
2% collagenase A (10 ml/g) (Roche) in Dulbecco’s modified Eagle’s
medium (DMEM)/F12. After enzymatic digestion, the tissue was
centrifuged at 250g for 4 min at 4°C. Fat was removed, and the pel-
let containing tissue microstructures was washed with phosphate-
buffered saline.R
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Fig. 6. Control of RANKL mRNA expression by PR signaling. (A) Rela-
tive RANKL mRNA levels determined by qRT-PCR in freshly isolated mouse
independent experiments are shown; data represent means ± SD of tripli-
cates after normalization to TBP (primers P0 and M0). (E) Scheme of primermammary organoids exposed for 30 min to R5020 or EtOH. Three in-
dependent experiments are shown; data represent means ± SD of tripli-
cates after normalization to TATA box–binding protein (TBP). (B) qRT-PCR
of RANKL mRNA in primary mouse mammary epithelial cells at different
times of actinomycin treatment in the presence or absence of R5020
plotted relative to initial value; data represent means ± SD of triplicates
after normalization to TBP. (C) mRNA half-lives of RANKL and control
mRNAs. (D) Ratio of RANKL primary and mature transcripts in mouse mam-
mary organoids stimulated for 4 hours with R5020 versus EtOH only. Threelocation within the mouse RANKL gene (e, exon; i, intron). (F) Fold induc-
tion of RANKL primary and mature transcripts with three distinct primer
sets in three additional experiments in which mouse mammary organoids
were stimulated for 4 hours with R5020 versus EtOH only. Data represent
means ± SD of triplicate measurements after normalization to TBP. (G)
Levels of RANKL primary and mature transcripts determined by Fluidigm
with three distinct primer sets in EpCAM+ cells isolated by FACS from tissue
microstructures from three different patients after 24 hours of treatment with
R5020 or EtOH. Data were normalized to HPRT.nceTranslationalMedicine.org 24 April 2013 Vol 5 Issue 182 182ra55 8
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Freshly isolated tissue microstructures were stimulated with R5020
(20 nM) and E2 (20 nM) (Sigma), RANKL (1 mg/ml), or OPG (10 or
20 mg/ml) in phenol red–free, serum-free DMEM/F12 either during or
after collagenase treatment.
Development of a correlation network
Network generation and integration of cell proliferation data were
accomplished with Cytoscape software (http://www.cytoscape.org).
The cell proliferation data were imported as fold change of the differ-
ent pairwise comparisons of individual samples. One “node” in this
network corresponds to an assayed sample, and the connection be-
tween them (“edge”) refers to the correlation between the two nodes
in the different experiments. Correlation networks were computed with
the Cytoscape plug-in ExpressionCorrelation (http://www.baderlab.
org/Software/ExpressionCorrelation), which facilitates assembly of a
network; nodes with similar “behavior” (cell proliferation fold change)
were connected and clustered on the basis of the Pearson correlation
coefficient for all pairwise comparisons. A cutoff of 0.9 was used, so
any correlations above this threshold value are displayed as an edge
between two nodes. The edge thickness corresponds to the correlation
coefficient level (0.9 to 0.99). Nodes were colored with a red-to-blue
gradient according to fold change proliferation index. Network images
were generated with Cytoscape version 2.8.2 and exported to Adobe
Illustrator for editing.
Statistical analysis
Statistical analysis was performed with R environment for box plots.
For all other data, two-tailed, paired Student’s t test was used to cal-
culate statistical significance; data are shown as means ± SD; P values
are indicated in the figures.SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/5/182/182ra55/DC1
Materials and Methods
Fig. S1. Heterogeneity of human breast tissue.
Fig. S2. RANKL expression in different mammary cell populations.
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